ATE289306T1 - N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen - Google Patents

N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen

Info

Publication number
ATE289306T1
ATE289306T1 AT00990204T AT00990204T ATE289306T1 AT E289306 T1 ATE289306 T1 AT E289306T1 AT 00990204 T AT00990204 T AT 00990204T AT 00990204 T AT00990204 T AT 00990204T AT E289306 T1 ATE289306 T1 AT E289306T1
Authority
AT
Austria
Prior art keywords
cyclin
carboxamide
oxazolyl
thiazolyl
thio
Prior art date
Application number
AT00990204T
Other languages
German (de)
English (en)
Inventor
Raj N Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE289306T1 publication Critical patent/ATE289306T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00990204T 1999-12-15 2000-12-07 N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen ATE289306T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US61662700A 2000-07-26 2000-07-26
PCT/US2000/033501 WO2001044242A1 (en) 1999-12-15 2000-12-07 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
ATE289306T1 true ATE289306T1 (de) 2005-03-15

Family

ID=27041008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00990204T ATE289306T1 (de) 1999-12-15 2000-12-07 N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen

Country Status (29)

Country Link
EP (1) EP1240166B1 (enExample)
JP (1) JP2003516987A (enExample)
KR (1) KR100738132B1 (enExample)
CN (1) CN1433416A (enExample)
AR (1) AR026974A1 (enExample)
AT (1) ATE289306T1 (enExample)
AU (1) AU783719B2 (enExample)
BR (1) BR0016424A (enExample)
CA (1) CA2394552A1 (enExample)
CO (1) CO5261565A1 (enExample)
CZ (1) CZ20022015A3 (enExample)
DE (1) DE60018205T2 (enExample)
DK (1) DK1240166T3 (enExample)
EG (1) EG24168A (enExample)
ES (1) ES2236034T3 (enExample)
HK (1) HK1049661B (enExample)
HU (1) HUP0301032A3 (enExample)
IL (2) IL149755A0 (enExample)
MX (1) MXPA02005870A (enExample)
MY (1) MY125768A (enExample)
NO (1) NO323726B1 (enExample)
NZ (1) NZ519120A (enExample)
PE (1) PE20011026A1 (enExample)
PL (1) PL364921A1 (enExample)
PT (1) PT1240166E (enExample)
RU (1) RU2002119016A (enExample)
TW (1) TWI273103B (enExample)
UY (1) UY26481A1 (enExample)
WO (1) WO2001044242A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
WO2002010162A1 (en) * 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
PT1532145E (pt) 2002-08-02 2007-01-31 Vertex Pharma Composiçoes de pirazole úteis como inibidores de gsk-3
US7392929B1 (en) 2004-07-26 2008-07-01 Zephyros, Inc. Weldable synthetic material
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8236128B2 (en) 2006-10-26 2012-08-07 Zephyros, Inc. Adhesive materials, adhesive parts formed therewith and their uses
WO2008063933A2 (en) * 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Pak modulators
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
KR100738132B1 (ko) 2007-07-10
EP1240166B1 (en) 2005-02-16
WO2001044242A1 (en) 2001-06-21
PT1240166E (pt) 2005-07-29
KR20020067546A (ko) 2002-08-22
PE20011026A1 (es) 2001-12-02
BR0016424A (pt) 2002-08-20
TWI273103B (en) 2007-02-11
CA2394552A1 (en) 2001-06-21
PL364921A1 (en) 2004-12-27
HUP0301032A3 (en) 2009-03-30
EG24168A (en) 2008-09-10
HK1049661A1 (en) 2003-05-23
IL149755A0 (en) 2002-12-01
CO5261565A1 (es) 2003-03-31
WO2001044242A9 (en) 2001-11-08
DE60018205T2 (de) 2006-02-16
NZ519120A (en) 2004-03-26
UY26481A1 (es) 2001-07-31
EP1240166A1 (en) 2002-09-18
CN1433416A (zh) 2003-07-30
DK1240166T3 (da) 2005-06-20
CZ20022015A3 (cs) 2003-02-12
NO20022817L (no) 2002-08-14
NO323726B1 (no) 2007-07-02
HUP0301032A2 (hu) 2003-08-28
ES2236034T3 (es) 2005-07-16
AR026974A1 (es) 2003-03-05
JP2003516987A (ja) 2003-05-20
MY125768A (en) 2006-08-30
AU2726401A (en) 2001-06-25
AU783719B2 (en) 2005-12-01
MXPA02005870A (es) 2003-01-28
HK1049661B (en) 2005-10-07
RU2002119016A (ru) 2004-01-10
DE60018205D1 (en) 2005-03-24
NO20022817D0 (no) 2002-06-13
IL149755A (en) 2009-09-22

Similar Documents

Publication Publication Date Title
ATE289306T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
NO20045220L (no) Heterocykliske inhibitorer for kinaser
ATE244235T1 (de) Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
NO20005673D0 (no) Heterocykliske inhibitorer av P38
NO20022864D0 (no) Aminotiazol inhibitorer av cyclin avhengige kinaser
NO20014535D0 (no) Inhibitorer av IMPDH-enzym
NO20031065D0 (no) Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
DE60316841D1 (de) Triazolderivate als inhibitoren von11-beta-hydroxysteroid-dehydrogenase-1
NO20033491D0 (no) Heterocykliske inhibitorer av ERK2 og anvendelser derav
ATE307128T1 (de) 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinon- derivative als protein-kinase inhibitoren
NO20002153D0 (no) Aminotiazol-inhibitorer for cyklin-avhengige kinaser
ATE493406T1 (de) Hydantoinderivate als mmp-inhibitoren
DE60005684D1 (de) Purin-derivative inhibitoren der tyrosi-protein kinase syk
DE60121032D1 (de) Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
DK1326853T3 (da) Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
HU0100973D0 (en) Use of heteroaryl substituted n-(indole-2-carbonyl)-amide derivatives for the treatment of infections
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
DE60118941D1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
NO20023675L (no) Heterocykliske amidderivater
FI962236L (fi) Heterosykliset bentseenisulfonyyli-imiinijohdannaiset IL-1:n toiminnan inhibiittoreina
DK1556378T3 (da) Acylderivater af 5-(2-(4-(1,2 benzisothiazol-3-yl)-1piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indo-2-on med neuroleptisk aktivitet
EP1222308A4 (en) INHIBITORS OF HISTONE ACETYL ANTIPROTOZOA TRANSFERASE
IS6696A (is) N-[5-[[[5-alkýl-2-oxazólýl]metýl]þíó]-2-þíazólýl]karboxamíð tálmar sýklínháðra kínasa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1240166

Country of ref document: EP

REN Ceased due to non-payment of the annual fee